Get the Stockscreener App
1,065.00
2.24%
23.35
After Hours:
1064.59
-0.41
-0.04%
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $1,065.00, with a volume of 3.47M.
It is up +2.24% in the last 24 hours and up +15.57% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$1,041.65
Open:
$1049.81
24h Volume:
3.47M
Relative Volume:
1.14
Market Cap:
$949.70B
Revenue:
$72.25B
Net Income/Loss:
$25.28B
P/E Ratio:
38.34
EPS:
27.781
Net Cash Flow:
$10.37B
1W Performance:
+5.98%
1M Performance:
+15.57%
6M Performance:
+0.50%
1Y Performance:
+48.91%
1-Day Range:
$1,047.07
$1,070.34
1-Week Range:
$978.87
$1,070.34
52-Week Range:
$623.78
$1,133.95
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY vs JNJ, ABBV, MRK, AZN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,065.00 | 928.88B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
234.34 | 557.82B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
215.70 | 378.98B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
122.41 | 286.20B | 65.51B | 8.93B | 14.12B | 3.5532 |
AZN
Astrazeneca Plc
|
187.03 | 294.27B | 60.48B | 10.40B | 8.05B | 3.3297 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-26 | Downgrade | HSBC Securities | Hold → Reduce |
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-16-25 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-15-25 | Reiterated | BofA Securities | Buy |
| Dec-15-25 | Reiterated | Goldman | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-10-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Reiterated | BMO Capital Markets | Outperform |
| Oct-14-25 | Upgrade | Erste Group | Hold → Buy |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| Aug-27-25 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-18-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Aug-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
Next-gen obesity drug helps patients lose 28% of body weight: Eli Lilly - NewsNation
The Most Important Healthcare Stock You're Not Watching - The Motley Fool
Lilly goes on $21B buying spree to build drug pipeline - Indianapolis Business Journal
Eli Lilly Highlights Positive Late-Stage Foundayo Data At Obesity Conference - Benzinga
LLY: Eli Lilly's Retatrutide Achieves Key Milestone in Phase III Trials - GuruFocus
Novo Nordisk faces new GLP-1 rival as Eli Lilly's triple agonist sets weight-loss record - Yahoo! Finance Canada
Eli Lilly Surge Puts S&P 500 Value Test In Focus - Kalkine Media
Eli Lilly Stock (LLY) Opinions on GLP-1 Drug Expansions - Quiver Quantitative
A Quick Look at Today's Ratings for Eli Lilly and Co(LLY.US), With a Forecast Between $1,250 to $1,400 - 富途牛牛
Experimental Drug Yields Dramatic Weight Loss - The New York Times
Eli Lilly (LLY) GLP-1 Drugs Show Promise in Cancer Treatment - GuruFocus
Ritatrutide Shows Promising Weight Loss Results, Boosting Eli Li - GuruFocus
Eli Lilly's next-generation obesity treatment "retatrutide" has ignited competition for next-generat.. - 매일경제
Eli Lilly's Retatrutide Shows 28% Weight Loss in Phase 3 Trial - 조선일보
Eli Lilly Sues COGIC Leaders Over Alleged $200 Million Drug Rebate Scheme - Christianity Today
Eli Lilly Raises $8.9 Billion in Debt Offering - The Globe and Mail
Why is Eli Lilly stock rallying today? By Investing.com - Investing.com Nigeria
Lilly to present oncology data at 2026 ASCO meeting By Investing.com - Investing.com Canada
Eli Lilly’s new weight-loss injection showed jaw-dropping results in study - Deseret News
Lilly accuses church-linked pharmacies, wholesalers and more of running $200M+ rebate fraud scheme - Fierce Pharma
New obesity drug from Lilly delivers major weight loss - The Hill
Eli Lilly's Triple Hormone Obesity Drug Shows Significant Weight Loss - Benzinga
Eli Lilly (LLY) Sees Strong Growth Driven by Mounjaro Momentum and GLP-1 Demand, Barclays Remains Bullish - Insider Monkey
New weight-loss shot appears to outperform other obesity drugs on market - The Guardian
Retatrutide, Eli Lilly's next obesity drug, fueled dramatic weight loss in clinical trial - LiveNOW from FOX
Engage Bio acquired by Lilly - The Pharma Letter
Eli Lilly (LLY) Reports Promising Weight Loss Results for Retatr - GuruFocus
A Next-Generation Drug Causes Dramatic Weight Loss, Eli Lilly Says - Time Magazine
Eli Lilly’s (LLY) Next-Generation Weight-Loss Drug Clears Big Hurdle - TipRanks
How does Lilly’s next-gen obesity drug compare to Novo’s (LLY) - Seeking Alpha
Another Triumph: Lilly’s triple G agonist scores in obesity - BioWorld News
Can Mounjaro, Zepbound & Foundayo Keep Fueling LLY's Growth Story? - Yahoo! Finance Canada
Where will all the workers park? Upper Macungie planners have questions about Lilly construction - The Morning Call
Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Report 2026 Featuring Major Players Novo Nordisk A/S, Eli Lilly and Company, and PfizerGlobal Forecast to 2030 and 2035 - Yahoo Finance Singapore
Lilly’s ‘triple-G’ drug leads to bariatric-surgery levels of weight loss in trial - statnews.com
Eli Lilly acquires Engage Biologics for up to $202 million - qz.com
Eli Lilly (LLY) Achieves Groundbreaking Weight Loss Results in P - GuruFocus
Eli Lilly (LLY) Maintains Buy Rating with $1,281 Price Target Fo - GuruFocus
Eli Lilly vs. Merck: Which Pharma Stock Looks Stronger Now? - Yahoo Finance
Lilly’s Experimental Shot Cuts Body Weight by 28% in Study - Bloomberg.com
Eli Lilly says next-gen obesity drug helps patients lose 28% of body weight - Reuters
RBC Capital Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,250 - Moomoo
New drug helped patients lose 28% of body weight: Eli Lilly - CTV News
Eli Lilly’s experimental shot cuts body weight by 28% in study - The Boston Globe
Eli Lilly stock (US5324571083): obesity and Alzheimer’s hopes keep valuation in focus - AD HOC NEWS
Could Viking Therapeutics Be the Next Eli Lilly? - The Motley Fool
Eli Lilly Experimental Drug Shows Surgery-Level Weight Loss in Phase 3 Trial - NCHStats
Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial | Eli Lilly and Company - investor.lilly.com
Eli Lilly maintains M&A streak with $202m Engage Bio buyout - Yahoo Finance
Eli Lilly stock gains on positive obesity drug trial data - Investing.com
Eli Lilly Enters $202 Million Agreement to Acquire Engage Bio - Pharmaceutical Executive
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.13%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):